Chongqing Yao Pharmaceutical Co., Ltd.

On July 25, 2023, Fosun Health Capital established by Fosun Pharma, reached a strategic partnership with Medicilon. Meanwhile StarMab Biology (Suzhou) (jointly invested by the innovation drug research fund of Fosun Group and Yaopharma) and Medicilon entered into a strategic cooperation for innovative drug IND research and application services. This strategic partnership indicates a significant step forward in the cooperation between Fosun Health Capital and Medicilon, with milestone for both parties' development. Cui Zhiping, Co-CEO and General Manager of Fosun Health Capital, Chen Chunlin, Founder and CEO of Medicilon, along with members from both sides attended the signing ceremony together and witnessed the contract. According to the strategic cooperation agreement, Medicilon will leverage its international perspective and rich experience in R&D to provide innovative drug enterprises invested by Fosun Health Capital with services?such as drug discovery, pharmaceutical research, preclinical research, IND registration declaration, etc., aiming to facilitate cooperation in 10 innovative drug IND projects. Medicilon will also provide professional opinions on the rationality of product development clinical programs, product success probability analysis, product market potential, etc. Furthermore, Medicilon will facilitate investment cooperation and create an ecosystem linking innovative drug investment and business cooperation. As for StarMab Biology, Medicilon will provide comprehensive and high-quality preclinical research services. Through this strategic cooperation, all parties will integrate respective technology, market and talent advantages, embrace the trends and technological changes in bioengineering and pharmaceutical industry, promote deeper and broader exploration in various fields, and explore the possibilities of new drug development.

　　On December 3, 2020, the kick-off meeting for the establishment of the New Chongqing Medical Institute was held in the meeting room 1008 of the Administration Building of Yaoyou Pharmaceutical Group. The chairman of the board of directors of the Yaoyou Pharmaceutical Group Mr. Liu Qiang, the co-president Ms. Zhang Yan and the main officials of the New Chongqing Medical Institute And the management attended the meeting. 　　The organizational structure and the appointment of members of the leadership team of the New Medical Institute were officially announced at the meeting: 　　Yaoyou Co-President Ms. Zhang Yan is the executive director and general manager, Mr. Lei Huangshu is the chief scientist, Mr. Cao Yaming is the deputy general manager in charge of R&D, and Ms. Fu Chencheng is the deputy general manager in charge of human administration. 　　Then, Dong Liu and Mr. Zhang respectively put forward ardent hopes and specific requirements for the strategic planning and development direction of the new hospital: 　　1. The new medical institute should inherit and carry forward the professional spirit of the older generation of medical institutes in pursuit of excellence and hard work, and continue the glorious history of the institute in the pharmaceutical industry. 　　2. Innovative genes will be deeply implanted in the new Chongqing Medical Engineering Institute. The first innovative drug of Yaoyou Group will be born in the Institute of Medical Engineering. This is also the overall strategic plan of Fosun Pharma Group. 　　3. The newly appointed young cadres should learn from the dedication and hard work of the leaders of the old medical institute, set an example, and lead the entire innovative drug team to move forward quickly, catch up with their peers, and achieve their goals as soon as possible. 　　4. The New Medical Institute must strengthen close cooperation with domestic universities and attract more outstanding talents with medical feelings to join. In the future, the New Medical Institute will be a high-quality talent team focusing on the research and development of innovative drugs. 　　Finally, the main members of the new management team also expressed their confidence and determination in the future development of the new hospital. 　　At present, the new Chongqing Medical Engineering Institute has officially opened on January 1, 2021. With the joint efforts of everyone, the company is looking forward to rebirth from the ashes, phoenix nirvana, and new highs.